News | October 09, 2023
Thermo Fisher Scientific expands St. Louis manufacturing for complex biologic treatments
Increased capability to produce medicines for challenging diseases including cancer
Increased capability to produce medicines for challenging diseases including cancer
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
The campus in Genome Valley will provide services in discovery chemistry & discovery biology, safety toxicology, bioanalytical services and formulation development to global pharmaceutical companies
This production block consists of chemical synthesis reactions and clean rooms areas to produce final API
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases
Subscribe To Our Newsletter & Stay Updated
